Vensica Therapeutics (Vensica), a clinical stage biopharmaceutical company, has closed a USD19 million investment round.
Vensica executed a strategic collaboration agreement with Merz Therapeutics in 2021 and the Merz Group is participating in Vensica’s financing with up to USD3 million, bringing the total round to up to USD19 million. The round was led by Israel Biotech Fund (IBF) with the participation of Laborie, Lew Pell, Agriline, and The Trendlines Group.
Merz Therapeutics, a business of the Merz Group, is a specialist in the field of neurotoxins. Vensica has exclusively licensed Merz’s botulinum neurotoxin A (Xeomin®) for needle-free use in urological procedures.
The funds raised will support the company’s phase II multicentre clinical trials in Europe and the USA.
